Trial reportAnnals of medicine2022
Weight loss via a low-carbohydrate diet improved the intestinal permeability marker, zonulin, in prostate cancer patients.
Trial report in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Gut microbiota and its metabolites: Key factors of drug resistance in the treatment of advanced prostate cancer (Review).Molecular medicine reports · 2026Review
- Ketogenic and Low-Carbohydrate Diets in Prostate Cancer: Metabolic Rationale, Preclinical Evidence, and Preliminary Clinical Data.Journal of clinical medicine · 2026Review
- Gut-prostate axis in prostate cancer: microbiome signatures, mechanistic insights, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Effect of Low-Carbohydrate Diets on C-Reactive Protein Level in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Food science & nutrition · 2025Review
- Obesity, dietary interventions and microbiome alterations in the development and progression of prostate cancer.Frontiers in immunology · 2024Review
- From microbes to medicine: harnessing the gut microbiota to combat prostate cancer.Microbial cell (Graz, Austria) · 2024Article
- Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAccumulating evidence suggest that gut microbiota may impact urologic health including prostate cancer (PC), potentially
methodsCAPS2 was a 6-month randomized controlled trial testing a LCD intervention vs. control on PC progression using prostate-specific antigen doubling time (PSADT) as the marker. All 45 participants had prior primary PC treatment, PSADT >3 and <36 months, and body mass index (BMI) ≥24 kg/m
resultsAt 6-month, zonulin decreased in the LCD arm (median -8.3%, IQR -16.6, 0.3%) while the control increased slightly (median 1.4%, IQR -3.0, 13.3%;
conclusionFuture studies are merited to examine further the potential association of IP with inflammation and to clarify if improvement in IP is associated with decreased PC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.